Human trials of the new novel vaccine against the Coronavirus begin in April in the UK and the United States.
The Imperial College of Britain is testing an animal vaccine in mid-February and will begin its trial on humans from April.
On the other hand, American company Moderna Oranio also said that their human vaccine trial could begin next month.
It is thought that the sixth case in Pakistan came to light on March 5, when the coronavirus has infected more than 97,000 people worldwide and over 333 have been killed and its treatment has not been available till now.
Those who suffer from this virus, Cod-19, are isolated and given medication based on their symptoms.
Imperial College began working on vaccine preparations in mid-January when Chinese scientists released genetic information for the new virus.
If tested successfully on humans, the vaccine will be tested by researchers in the real world for people at risk for the infection.
Imperial College professor Robin Shattock and his team developed the vaccine 14 days after receiving genetic sequestration of the virus from China and have been testing the animals since February 10.
Unlike traditional antibody vaccines, Imperial College's vaccine is injected into the new genetic code, which is derived from a protein that has been discovered at the level of the corona virus, which can cause an immune response in the body.
According to Professor Robin, we have a technology that helps create a vaccine at a pace that has never been realized before, most vaccines are completed in 5 to 6 years, then from one Prepare for 2 years and then the trials begin.
Well, this is not the only university in the UK, in fact, many universities are working on the vaccine.
According to Professor Jonathan Heaney of the University of Cambridge's Viral Zonetics Laboratory, his team is in the pre-clinical stage of vaccine and is advancing rapidly.
Similarly, a vaccine is being worked out by Oxford University.
Earlier in the day, a delegation of pharmaceutical companies met with US President Donald Trump to assure the prompt manufacture of vaccines and anti-viral drugs.
To date, 35 companies and companies are operating in this regard worldwide.
Human trials can begin within 6 weeks, with the vaccine being ready in 12 to 18 months, said Dr. Anthony Fucci, head of the US National Institute of Allergy and Infectious Disease.
According to the CEO of InnovCompany, the vaccine is being tested on animals and there will be 1 million doses available by the end of this year.
Another American company, Moderna, will begin testing the vaccine for 45 people in April and says the vaccine will be available by February next year.
Similarly, many US companies plan to start testing their own vaccines on humans over the next few months.
The vaccine is being tested on animals by Queensland University, while an Israeli company is set to begin testing humans in the next 8 to 10 weeks.
Chinese Deputy Minister of Science and Technology Shu Nan Ping also confirmed that a vaccine trial will be launched on humans by the end of April.
But the preparation of an effective vaccine requires considerable time and may initially be specific to medical staff and critically ill persons, which is why the preparation of medicines is also being worked on.
The best remdesivir drug so far is being called an antiviral drug, which is currently being tested on 13 patients at the US National Institute of Health.
China has also approved the use of Favilavir, an anti-viral drug, while Chloroquine, Phosphate and Remdesivir are being tested.